This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Template:SubstanceBox/LSD: Difference between revisions
Jump to navigation
Jump to search
>Kenan m add common names |
>Graham m wiki ref formatting |
||
| Line 71: | Line 71: | ||
|SublingualROA_Collapsed=false | |SublingualROA_Collapsed=false | ||
|SublingualROA_Caption= | |SublingualROA_Caption= | ||
|SublingualROA_Bioavailability=[[Sublingual min bioavailability::71]]% - [[Sublingual max bioavailability::71]]%<ref>Dolder, P. C., Schmid, Y., Haschke, M., Rentsch, K. M., | |SublingualROA_Bioavailability=[[Sublingual min bioavailability::71]]% - [[Sublingual max bioavailability::71]]%<ref>{{cite journal | vauthors=((Dolder, P. C.)), ((Schmid, Y.)), ((Haschke, M.)), ((Rentsch, K. M.)), ((Liechti, M. E.)) | journal=International Journal of Neuropsychopharmacology | title=Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans | volume=19 | issue=1 | pages=1–7 | date= January 2016 | url=https://academic.oup.com/ijnp/article-lookup/doi/10.1093/ijnp/pyv072 | issn=1461-1457 | doi=10.1093/ijnp/pyv072}}</ref> | ||
|SublingualROA_Microdose= | |SublingualROA_Microdose= | ||
|SublingualROA_Threshold=[[Sublingual threshold dose::15]] [[Sublingual dose units::µg]] | |SublingualROA_Threshold=[[Sublingual threshold dose::15]] [[Sublingual dose units::µg]] | ||
Revision as of 23:37, 29 June 2022
| SubstanceBox/LSD | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
|||||||||||||||||||||||||||||||||||
| Chemical Nomenclature | |||||||||||||||||||||||||||||||||||
| Common names | LSD, LSD-25, Lucy, L, Acid, Cid, Tabs, Blotter | ||||||||||||||||||||||||||||||||||
| Substitutive name | d-Lysergic acid diethylamide | ||||||||||||||||||||||||||||||||||
| Systematic name | (6aR,9R)-N,N-Diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide | ||||||||||||||||||||||||||||||||||
| Class Membership | |||||||||||||||||||||||||||||||||||
| Psychoactive class | Psychedelic | ||||||||||||||||||||||||||||||||||
| Chemical class | Lysergamide | ||||||||||||||||||||||||||||||||||
| Routes of Administration | |||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
- ↑ Dolder, P. C., Schmid, Y., Haschke, M., Rentsch, K. M., Liechti, M. E. (January 2016). "Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans". International Journal of Neuropsychopharmacology. 19 (1): 1–7. doi:10.1093/ijnp/pyv072. ISSN 1461-1457.